Are you Dr. Bonner?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 43 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
12680 Olive Blvd
Ste 200
Saint Louis, MO 63141Phone+1 314-251-8892Fax+1 314-251-8894
Summary
- Dr. Jo Bonner, MD is a board certified neurologist in Saint Louis, Missouri. She is currently licensed to practice medicine in Missouri and Ohio. She is affiliated with Mercy Hospital St. Louis.
Education & Training
SSM Health/Saint Louis University School of MedicineResidency, Neurology, 1990 - 1991
University of Cincinnati Medical Center/College of MedicineResidency, Neurology, 1988 - 1990
University of Missouri-ColumbiaResidency, Neurology, 1987 - 1988- University of Missouri-ColumbiaResidency, Internal Medicine, 1985 - 1987
University of Missouri-Columbia School of MedicineClass of 1985
Certifications & Licensure
MO State Medical License 1985 - 2025
OH State Medical License 1988 - 1994- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache Start of enrollment: 2014 Jul 07
- A Study of Galcanezumab in Participants With Chronic Cluster Headache Start of enrollment: 2015 Jun 18
Publications & Presentations
PubMed
- 10 citationsReduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical tri...Stewart J. Tepper, Messoud Ashina, Uwe Reuter, Yngve Hallström, Gregor Broessner
The Journal of Headache and Pain. 2021-07-23 - 10 citationsThe Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response.Gregor Broessner, Uwe Reuter, Jo H. Bonner, David W. Dodick, Yngve Hallstrom
Headache. 2020-10-01 - 4 citationsEvaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraineVirginia L. Stauffer, Shufang Wang, Jo Bonner, ByungKun Kim, Rohit Bhandari
BMC Neurology. 2020-05-19
Press Mentions
Rural Health AdvocateSeptember 15th, 2021- UK Secures 90 Million COVID-19 Vaccine Doses; Germany Hotspot Numbers Four Times Previous EstimateAugust 15th, 2020
Theranica: New Publication Compares Remote Electrical Neuromodulation for Acute Treatment of Migraine to Treatment with Acute MedicationsJuly 24th, 2019
